Federal Register of Legislation - Australian Government

Primary content

PB 34 of 2019 Determinations/Health as made
This instrument amends the National Health (Originator Brand) Determination 2015 (PB 100 of 2015) to determine an originator brand of a new pharmaceutical item for an existing Pharmaceutical Benefit Schedule listed drug on the F2 formulary.
Administered by: Health
Registered 30 Apr 2019

PB 34 of 2019

National Health (Originator Brand) Amendment Determination 2019 (No. 3)

National Health Act 1953

I, SEAN LANE, Acting Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Determination under subsection 99ADB (6B) of the National Health Act 1953.

Dated       29 April 2019

 

 

 

 

 

 

SEAN LANE

Acting Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health



1              Name of Determination

                 (1)     This Determination is the National Health (Originator Brand) Amendment Determination 2019 (No. 3).

(2)     This Determination may also be cited as PB 34 of 2019.

2              Commencement

                This Determination commences on 1 May 2019.

3              Amendments to PB 100 of 2015

                Schedule 1 amends the National Health (Originator Brand) Determination 2015 (PB 100 of 2015).


Schedule 1     Amendments

(section 3)

 [1]                  Schedule 1 (table item 16A)

Repeal the item:

16A

Apomorphine

Apomine

Apomine Solution for Infusion

 

 

Substitute:

16A

Apomorphine

Apomine

Apomine Intermittent

Apomine Solution for Infusion